Inhibition of AXL with a specific inhibitor BGB324 (currently in clinical trial for AML) downregulated phospho-JAK3, phospho-STAT3, and phospho-ERK in HS578T and MDA231 cells (Fig. 4B), indicating AXL activates JAK/STAT and MEK/ERK pathways in these cells. Here, STAT3 is linked to acute myeloid leukemia.